![Michael Buschle](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Michael Buschle
Directeur/Membre du Conseil chez
VICORE PHARMA HOLDING AB
Profil
Michael Buschle was the founder of Intercell AG, serving as Chief Scientific Officer from 1997 to 2012.
Current jobs include Director at Vicore Pharma Holding AB since 2023 and Advisor at HBM Partners AG since 2017.
Former jobs include Independent Director at Y-mAbs Therapeutics, Inc. from 2017 to 2018 and Chief Scientific Officer at Glenmark Pharmaceuticals Ltd. Education includes a doctorate from the University of London.
Postes actifs de Michael Buschle
| Sociétés | Poste | Début |
|---|---|---|
| VICORE PHARMA HOLDING AB | Directeur/Membre du Conseil | 01/01/2023 |
HBM Partners AG
 HBM Partners AG Investment ManagersFinance HBM Partners invests in private and public companies located in India, China, North America and Europe. The firm focuses on biopharma, medtech, diagnostics and healthcare sectors. It provides financing for early, buyout and growth stage capital requirements with an investment size from USD 5 to 50 million. | Private Equity Investor | 01/01/2017 |
Anciens postes connus de Michael Buschle
| Sociétés | Poste | Fin |
|---|---|---|
| YMAS THER | Directeur/Membre du Conseil | 11/12/2018 |
Intercell AG
 Intercell AG Pharmaceuticals: MajorHealth Technology Manufactures drugs and medicines | Fondateur | 01/01/2012 |
| GLENMARK PHARMACEUTICALS LIMITED | Directeur Technique/Scientifique/R&D | - |
Formation de Michael Buschle
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
38
Relations au 1er degré
6
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 6 |
|---|---|
HBM Partners AG
HBM Partners AG Investment ManagersFinance HBM Partners invests in private and public companies located in India, China, North America and Europe. The firm focuses on biopharma, medtech, diagnostics and healthcare sectors. It provides financing for early, buyout and growth stage capital requirements with an investment size from USD 5 to 50 million. | Finance |
Intercell AG
Intercell AG Pharmaceuticals: MajorHealth Technology Manufactures drugs and medicines | Health Technology |
Glenmark Pharmaceuticals Ltd.
 Glenmark Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Develops and manufactures pharmaceuticals | Health Technology |
University of London
 University of London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Vicore Pharma Holding AB
 Vicore Pharma Holding AB Pharmaceuticals: MajorHealth Technology Engages in research and development of drugs for lung diseases | Health Technology |
Y-mAbs Therapeutics, Inc.
 Y-mAbs Therapeutics, Inc. BiotechnologyHealth Technology Develops radioimmunotherapy and antibody-based oncology therapies for treating cancer | Health Technology |
